MammaTyper® is a new tool for subtyping breast cancer.
READ MORE +ABOUT US
Cerca Biotech is the European subsidiary of Shuwen Biotech, a highly reputable and innovative molecular and point of care diagnostics organisation. Shuwen and Cerca are passionate about healthcare and are working to create world-leading innovations in the fields of Oncology and Women’s Health.
Quantitative RT-qPCR assay (CE marked IVD)
Clinical value validated in numerous performance evaluation studies
Clinical value validated in numerous performance evaluation studies
Ki67 testing could play a vital role in helping tailor treatments for people with ER-positive breast cancers. However, long-standing problems with immunohistochemistry (IHC) are preventing patients from benefitting from this biomarker. In this blog post, we outline the potential of Ki67 in the neoadjuvant setting, and why we need to look at alternatives to IHC.
Endocrine therapy has for decades been one of the key treatment choices for hormone receptor-positive breast cancer. Yet predicting who will and won’t benefit from therapy remains a challenge. In this article, we explore whether gene expression profiling with MammaTyper® may make up for the shortfalls of IHC in this area.
We spoke to Dr Scatena about recent work he presented at the European Breast Cancer Conference in Milan, using MammaTyper® to predict the response to neoadjuvant chemotherapy in HER2-positive breast cancers. We also discussed the role that artificial intelligence will have in pathology in the future.